Breaking News, Trials & Filings

FDA Approves Celltrion’s Biosimilar to ACTEMRA

AVTOZMA is indicated for the treatment of multiple diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis and more.

Author Image

By: Charlie Sternberg

Associate Editor

The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to ACTEMRA. AVTOZMA is indicated for the treatment of multiple diseases including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19). “Introducing both IV and SC formula...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters